- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Pharming Group NV(PHAR)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PHAR
11/13/2026: PHAR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Pharming Group NV is a biopharmaceutical company specializing in protein replacement and targeted therapies for rare diseases. Its main business strength lies in the successful commercialization of RUCONEST and the launch of its newer therapy, JOENJA, which address unmet medical needs. The primary investment story centers on the company’s transition from a single-product developer to a broader, global rare-disease organization. Key risks include the inherent uncertainty of clinical trials, potential competition in the rare disease space, and reliance on a small number of products. The stock is best suited for growth-oriented investors who can tolerate biotech-sector volatility and should monitor upcoming clinical results and global product uptake.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers exposure to the scaling phase of niche rare-disease therapies. |
| Momentum investor | Mixed fit | Momentum is conditional on positive clinical data readouts or successful commercial expansion reports. |
| Value investor | Weak fit | The company is in a growth phase with high R&D spending, making it less attractive based on traditional valuation metrics. |
| Dividend investor | Weak fit | Pharming does not prioritize dividend payments, focusing capital on business growth. |
| Low-risk investor | Weak fit | The company is subject to the inherent volatility of clinical-stage and niche biopharmaceutical stocks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks often experience sharp price movements based on news cycles and clinical results. |
| Valuation risk | Medium | Future performance is heavily dependent on the market adoption of newer products like JOENJA. |
| Competition risk (rare disease market) | Medium / high | Large incumbents like Takeda have deeper pockets for marketing and market access. |
| Business quality | Medium | The company is evolving into a profitable commercial enterprise but is still building its franchise. |
| Dividend income | Low / none | Investors should not expect income, as all capital is reinvested. |
| Execution risk | Medium | Success depends on the effective global rollout of existing and future therapies. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 891.80M USD | Price to earnings Ratio 39.38 | 1Y Target Price 35.7 |
Price to earnings Ratio 39.38 | 1Y Target Price 35.7 | ||
Volume (30-day avg) 14.4K shares | Beta 0.05 | 52 Weeks Range 9.11 - 21.34 | Updated Date 11/14/2026 |
52 Weeks Range 9.11 - 21.34 | Updated Date 11/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.32 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -42.66% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Sales | Global sales of RUCONEST and JOENJA. | The company earns money primarily by selling specialized drugs for rare diseases to healthcare providers. |
| Geography | North America, Europe, and Rest of World. | The US market is a primary driver of revenue, but global reach is expanding. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-27 | When Before Market | Estimate 0.33 | Actual 0.3 |
Profitability
Profit Margin 6.25% | Operating Margin (TTM) 12.78% |
Management Effectiveness
Return on Assets (TTM) 6.37% | Return on Equity (TTM) 8.7% |
Valuation
Trailing PE 39.38 | Forward PE 256.41 | Enterprise Value 817.29M | Price to Sales(TTM) 2.31 |
Enterprise Value 817.29M | Price to Sales(TTM) 2.31 | ||
Enterprise Value to Revenue 2.16 | Enterprise Value to EBITDA 20.73 | Shares Outstanding 70.78M | Shares Floating 67.32M |
Shares Outstanding 70.78M | Shares Floating 67.32M | ||
Percent Insiders - | Percent Institutions 0.13 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

